Research programme: bacterial therapeutics - Novome Biotechnologies
Latest Information Update: 24 Mar 2022
At a glance
- Originator Novome Biotechnologies
- Class Anti-inflammatories; Antineoplastics; Bacteria; Gene therapies; Irritable bowel syndrome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Irritable bowel syndrome
- Research Cancer; Ulcerative colitis
Most Recent Events
- 01 Mar 2022 Caribou Biosciences has patent protection for next-generation CRISPR genome editing technology worldwide
- 01 Mar 2022 Caribou Biosciences has patents pending for next-generation CRISPR genome editing technology worldwide
- 28 Jun 2021 Early research in Cancer in USA (unspecified route) (Novome Biotechnologies pipeline, June 2021)